2012

INC Research launches strategic advisory services unit

Wednesday, December 5, 2012

INC Research, a therapeutically focused CRO, has launched INC Research Strategic Advisory Services, a new global business unit dedicated to providing biopharmaceutical customers with world-class consulting capabilities in the areas of drug development and commercialization, regulatory consulting and submissions and quality assurance.

[Read More]

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

[Read More]